ALK and non-small cell lung carcinoma: In our study, we use computational techniques (molecular modelling, molecular docking, molecular dynamics, and virtual screening) to identify new characteristics in existing drugs to propose them as candidates for pharmacological repositioning for ALK+ NSCLC treatment.